Agios Pharmaceuticals (AGIO) Cash from Financing Activities (2012 - 2026)

Agios Pharmaceuticals' Cash from Financing Activities history runs 15 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 28.35% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (down 10.41% YoY) and the FY2025 annual result came in at $8.7 million, down 39.93% from the prior year.
• Cash from Financing Activities was $2.1 million for Q1 2026 at Agios Pharmaceuticals, down from $2.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $5.9 million in Q1 2024 and bottomed at -$67000.0 in Q2 2022.
• A 5-year average of $1.9 million and a median of $1.6 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 3750.0% — and 2025, when it tumbled 94.09%.
• Agios Pharmaceuticals' Cash from Financing Activities stood at $22000.0 in 2022, then jumped by 3750.0% to $847000.0 in 2023, then soared by 471.66% to $4.8 million in 2024, then tumbled by 47.19% to $2.6 million in 2025, then dropped by 18.73% to $2.1 million in 2026.
• Business Quant data shows AGIO's Cash from Financing Activities at $2.1 million in Q1 2026, $2.6 million in Q4 2025, and $4.4 million in Q3 2025.